Exelixis | EXEL - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 243.27M 14.49M 2026-03
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Akebia Therapeutics USD 47.28M 1.7M 2025-12
Amgen USD 6.89B 415M 2025-12
AstraZeneca USD 12.61B 225M 2026-03
Bayer EUR 6.94B 1.58B 2025-12
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Cytokinetics USD 19.2M 1.44M 2026-03
Eisai JPY 153.41B 15.44B 2026-03
Eli Lilly USD 15.92B 1.33B 2025-12
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Exelixis USD 590.86M 18.68M 2026-03
Genmab DKK 977M 13M 2025-12
Glaxosmithkline GBP 8.75B 2.92B 2025-09
Incyte USD 1.17B 217.51M 2026-03
Ionis Pharmaceuticals USD 243M 48M 2026-03
MacroGenics USD 31.11M 30.14M 2025-12
Merck USD 10.85B 2.57B 2025-12
Moderna USD -566M 792M 2026-03
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novartis USD 10.07B 184M 2026-03
Pfizer USD 11.04B 1.24B 2026-03
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sanofi EUR 8.45B 3.02B 2025-12
Takeda JPY 688.84B 101.71B 2026-03
Ultragenyx Pharmaceutical USD 106M 72M 2026-03
Xencor USD 21M 22.61M 2025-09